A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker…

By D. Cameron, M. Casey, M. Press, Deborah L. Lindquist, T. Pieńkowski, C. Romieu, S. Chan, A. Jagiełło-Gruszfeld, B. Kaufman, J. Crown and 14 more. Breast Cancer Research and Treatment, 2008

823 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/38a852fe4778656ad668faad03f582f938d53bcf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Baselga
2. L. Gianni

Citations in the corpus

• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. (2010, background): “Lapatinib is established as effective treatment forErbB2-positive locallyadvancedBCorMBC,(14-17) including cancers progressing on prior trastuzumab-based therapy.(14) Preclinical models demonstrated the interaction of lapatinib with trastuzumab as synergistic and resulting in enhanced apoptosis in E”
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010, result): “The efficacy and, in particular, the safety of the pertuzumab and trastuzumab combination compare favorably with these results because lapatinib plus capecitabine resulted in a high incidence of grade 3 or 4 diarrhea and rash (14% and 9%, respectively).(24) Therefore, it is conceivable that a nonche”